On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza clinical trial in China. The coronavirus test development and clinical trial is in collaboration with Dr. Wang Guangfa, head of the Department of Pulmonary Medicine at Peking University First Hospital in Beijing.

The clinical trial results were to be submitted under an ’emergency use’ authorization in both China and the U.S.